European guidelines (S1) on the use of high-dose intravenous immunoglobulin in dermatology
Background and objectives Treatment of severe dermatological autoimmune diseases and toxic epidermal necrolysis (TEN) with high-dose intravenous immunoglobulin (IVIg) is a well-established procedure in dermatology. As treatment with IVIg is usually considered for rare clinical entities or severe cas...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
February 2017
|
| In: |
Journal der Deutschen Dermatologischen Gesellschaft
Year: 2017, Jahrgang: 15, Heft: 2, Pages: 228-241 |
| ISSN: | 1610-0387 |
| DOI: | 10.1111/ddg.13013 |
| Online-Zugang: | Verlag, Volltext: http://dx.doi.org/10.1111/ddg.13013 Verlag, Volltext: https://onlinelibrary.wiley.com/doi/abs/10.1111/ddg.13013 
|
| Verfasserangaben: | Alexander Enk, Eva Hadaschik, Rüdiger Eming, Gerhard Fierlbeck, Lars French, Giampiero Girolomoni, Michael Hertl, Stephen Jolles, Sarolta Karpati, Kerstin Steinbrink, Georg Stingl, Beatrix Volc‐Platzer, Detlef Zillikens |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1582707332 | ||
| 003 | DE-627 | ||
| 005 | 20230427193301.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 181108s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/ddg.13013 |2 doi | |
| 035 | |a (DE-627)1582707332 | ||
| 035 | |a (DE-576)512707332 | ||
| 035 | |a (DE-599)BSZ512707332 | ||
| 035 | |a (OCoLC)1341022520 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Enk, Alexander |d 1963- |e VerfasserIn |0 (DE-588)1032757140 |0 (DE-627)739272535 |0 (DE-576)166173517 |4 aut | |
| 245 | 1 | 0 | |a European guidelines (S1) on the use of high-dose intravenous immunoglobulin in dermatology |c Alexander Enk, Eva Hadaschik, Rüdiger Eming, Gerhard Fierlbeck, Lars French, Giampiero Girolomoni, Michael Hertl, Stephen Jolles, Sarolta Karpati, Kerstin Steinbrink, Georg Stingl, Beatrix Volc‐Platzer, Detlef Zillikens |
| 264 | 1 | |c February 2017 | |
| 300 | |a 14 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a First published: 30 December 2016 | ||
| 500 | |a Gesehen am 08.11.2018 | ||
| 520 | |a Background and objectives Treatment of severe dermatological autoimmune diseases and toxic epidermal necrolysis (TEN) with high-dose intravenous immunoglobulin (IVIg) is a well-established procedure in dermatology. As treatment with IVIg is usually considered for rare clinical entities or severe cases, the use of immunoglobulin is not generally based on data from randomized controlled trials usually required for evidence-based medicine. Since the indications for the use of IVIg are rare, it is unlikely that such studies will be available in the foreseeable future. Because first-line use is limited by the high costs of IVIg, the first clinical guidelines on the use of IVIg in dermatological conditions were established in 2008 and renewed in 2011. Methods The European guidelines presented here were prepared by a panel of experts nominated by the EDF and EADV. The guidelines were developed to update the indications for treatment currently considered effective and to summarize the evidence for the use of IVIg in dermatological autoimmune diseases and TEN. Results and conclusion The current guidelines represent consensual expert opinions and definitions on the use of IVIg reflecting current published evidence and are intended to serve as a decision-making tool for the use of IVIg in dermatological diseases. | ||
| 700 | 1 | |a Hadaschik, Eva |e VerfasserIn |0 (DE-588)1054876916 |0 (DE-627)792376684 |0 (DE-576)410969842 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |a Deutsche Dermatologische Gesellschaft |t Journal der Deutschen Dermatologischen Gesellschaft |d Berlin : Wiley-Blackwell, 2003 |g 15(2017), 2, Seite 228-241 |h Online-Ressource |w (DE-627)362755833 |w (DE-600)2099463-1 |w (DE-576)103373837 |x 1610-0387 |7 nnas |
| 773 | 1 | 8 | |g volume:15 |g year:2017 |g number:2 |g pages:228-241 |g extent:14 |a European guidelines (S1) on the use of high-dose intravenous immunoglobulin in dermatology |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/ddg.13013 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u https://onlinelibrary.wiley.com/doi/abs/10.1111/ddg.13013 |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20181108 | ||
| 993 | |a Article | ||
| 994 | |a 2017 | ||
| 998 | |g 1054876916 |a Hadaschik, Eva |m 1054876916:Hadaschik, Eva |d 910000 |d 911300 |d 50000 |e 910000PH1054876916 |e 911300PH1054876916 |e 50000PH1054876916 |k 0/910000/ |k 1/910000/911300/ |k 0/50000/ |p 2 | ||
| 998 | |g 1032757140 |a Enk, Alexander |m 1032757140:Enk, Alexander |d 910000 |d 911300 |e 910000PE1032757140 |e 911300PE1032757140 |k 0/910000/ |k 1/910000/911300/ |p 1 |x j | ||
| 999 | |a KXP-PPN1582707332 |e 3030648044 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"note":["First published: 30 December 2016","Gesehen am 08.11.2018"],"recId":"1582707332","name":{"displayForm":["Alexander Enk, Eva Hadaschik, Rüdiger Eming, Gerhard Fierlbeck, Lars French, Giampiero Girolomoni, Michael Hertl, Stephen Jolles, Sarolta Karpati, Kerstin Steinbrink, Georg Stingl, Beatrix Volc‐Platzer, Detlef Zillikens"]},"origin":[{"dateIssuedDisp":"February 2017","dateIssuedKey":"2017"}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"id":{"doi":["10.1111/ddg.13013"],"eki":["1582707332"]},"language":["eng"],"relHost":[{"corporate":[{"role":"aut","display":"Deutsche Dermatologische Gesellschaft"}],"type":{"media":"Online-Ressource","bibl":"periodical"},"language":["ger","eng"],"id":{"doi":["10.1111/(ISSN)1610-0387"],"eki":["362755833"],"issn":["1610-0387"],"zdb":["2099463-1"]},"disp":"Deutsche Dermatologische GesellschaftJournal der Deutschen Dermatologischen Gesellschaft","recId":"362755833","pubHistory":["1.2003 -"],"note":["Gesehen am 03.03.10"],"origin":[{"publisherPlace":"Berlin ; Berlin","dateIssuedDisp":"2003-","publisher":"Wiley-Blackwell ; Blackwell","dateIssuedKey":"2003"}],"part":{"volume":"15","pages":"228-241","text":"15(2017), 2, Seite 228-241","year":"2017","extent":"14","issue":"2"},"physDesc":[{"extent":"Online-Ressource"}],"titleAlt":[{"title":"JDDG"}],"title":[{"subtitle":"JDDG = Journal of the German Society of Dermatology","title":"Journal der Deutschen Dermatologischen Gesellschaft","title_sort":"Journal der Deutschen Dermatologischen Gesellschaft"}],"titleTranslated":[{"translated":"Journal of the German Society of Dermatology"}]}],"person":[{"role":"aut","given":"Alexander","family":"Enk","display":"Enk, Alexander"},{"role":"aut","display":"Hadaschik, Eva","family":"Hadaschik","given":"Eva"}],"physDesc":[{"extent":"14 S."}],"title":[{"title":"European guidelines (S1) on the use of high-dose intravenous immunoglobulin in dermatology","title_sort":"European guidelines (S1) on the use of high-dose intravenous immunoglobulin in dermatology"}]} | ||
| SRT | |a ENKALEXANDEUROPEANGU2017 | ||